Latest Roche News & Updates

See the latest news and media coverage for Roche. We track all announcements, press releases, and industry mentions in real time, all in one place.

Roche

Pharmaceuticals and diagnostics company

roche.com

Headquarters: Switzerland 🇨🇭 , Switzerland
Company type: Public company
Number of employees: 100,000+
Industry: Pharmaceuticals

Last updated Today

Latest news about Roche

In short: Roche reported 6% sales growth, advanced its Alzheimer's drug trontinemab, and received multiple FDA priority reviews for new therapies.

Company announcements

September 10 Roche

Roche receives Priority Review for Enspryng in MOGAD

FDA acceptance is based on Phase III METEOROID results showing a 68% relapse reduction. Approval decision is expected by January 2027.

August 6 Roche

Roche reports 2025 financial results and key scientific advancements

The company achieved CHF 61.5 billion in group sales with a CHF 9.80 dividend proposal while reducing scope 1 and 2 emissions by 34%. Progress spans oncology, neurology, diagnostics AI integration, and expanded patient support programs.

July 24 Roche

Roche's Susvimo recommended for EU approval in nAMD

The first continuous delivery treatment offers an alternative to frequent eye injections, maintaining vision with as few as two treatments per year.

July 23 Roche

Roche reports 6% revenue growth in the first half of 2026

Group revenue rose by 6% at constant exchange rates, core earnings per share by 9%.

Media coverage

September 13 Yahoo Finance

Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and...

September 12 Psychiatric Times

Trontinemab Shows Promise for Treatment of Alzheimer Disease in New Data at CTAD | Psychiatric Times

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid...

September 10 Yahoo Finance

U.S. FDA grants Priority Review for Roche's Enspryng for MOGAD, an autoimmune disease with no approved treatments

If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease)Filing acceptance is based on the Phase III...

September 5 BusinessDay

Roche's alzheimer's drug clears plaques in 28 weeks, faces 2028 test to slow memory loss

Roche's experimental Alzheimer's drug, trontinemab, has cleared harmful protein deposits from the brains of nine out of 10 patients within...

Never miss news about Roche

Track Roche and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Roche competitors & trending companies

Browse news for competitors to Roche and other trending companies.